Black Diamond Therapeutics (BDTX)

Executive Summary

Black Diamond Therapeutics is a public biotechnology company pioneering MasterKey therapies designed to target broad genetically defined patient populations with non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Its small-molecule inhibitors are engineered to overcome resistance, minimize wild-type toxicities, and achieve brain penetration for effective CNS disease treatment. The company’s lead candidate, BDTX-1535, is a potent, brain-penetrant EGFR inhibitor targeting both classical and atypical EGFR mutations in NSCLC, including those in the C797S resistance setting. Additionally, BDTX-4933 targets RAF alterations across tumors, addressing a key driver in multiple cancers. Black Diamond has made significant progress advancing its pipeline toward key inflection points. The company is expected to report clinical data from its Phase 1/2 studies of BDTX-1535 in EGFR-mutant NSCLC and BDTX-4933 in RAF-altered tumors in the coming quarters. These readouts are pivotal for demonstrating the breadth of its MasterKey approach and validating its strategy in CNS-active, mutant-selective therapies. With a cash runway extending into 2027, Black Diamond is well-positioned to execute on its development plans and potentially define a new standard of care in genetically defined oncology subsets.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data for BDTX-1535 in EGFR-mutant NSCLC (including C797S)70% success
• Q1 2027Phase 1/2 data for BDTX-4933 in RAF-altered advanced solid tumors50% success
• H1 2027Initiation of registration-directed study for BDTX-1535 in EGFR-mutant NSCLC with brain metastases60% success